| Literature DB >> 34302789 |
Mitchell G Miglis1, Charles H Adler2, Elena Antelmi3, Dario Arnaldi4, Luca Baldelli5, Bradley F Boeve6, Matteo Cesari7, Irene Dall'Antonia8, Nico J Diederich9, Kathrin Doppler10, Petr Dušek8, Raffaele Ferri11, Jean-François Gagnon12, Ziv Gan-Or13, Wiebke Hermann14, Birgit Högl7, Michele T Hu15, Alex Iranzo16, Annette Janzen17, Anastasia Kuzkina10, Jee-Young Lee18, Klaus L Leenders19, Simon J G Lewis20, Claudio Liguori21, Jun Liu22, Christine Lo15, Kaylena A Ehgoetz Martens23, Jiri Nepozitek8, Giuseppe Plazzi24, Federica Provini25, Monica Puligheddu26, Michal Rolinski27, Jan Rusz28, Ambra Stefani7, Rebekah L S Summers29, Dallah Yoo30, Jennifer Zitser31, Wolfgang H Oertel32.
Abstract
Patients with isolated rapid-eye-movement sleep behaviour disorder (RBD) are commonly regarded as being in the early stages of a progressive neurodegenerative disease involving α-synuclein pathology, such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. Abnormal α-synuclein deposition occurs early in the neurodegenerative process across the central and peripheral nervous systems and might precede the appearance of motor symptoms and cognitive decline by several decades. These findings provide the rationale to develop reliable biomarkers that can better predict conversion to clinically manifest α-synucleinopathies. In addition, biomarkers of disease progression will be essential to monitor treatment response once disease-modifying therapies become available, and biomarkers of disease subtype will be essential to enable prediction of which subtype of α-synucleinopathy patients with isolated RBD might develop.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34302789 PMCID： PMC8600613 DOI： 10.1016/S1474-4422(21)00176-9
Source DB: PubMed Journal: Lancet Neurol ISSN： 1474-4422 Impact factor: 44.182